EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care

Joana Caetano iD, Ana Marta Pires, Carlos Costa, Rui Bergantim, Adriana Roque iD, Patrícia Ferraz, Maria Rosário Cunha, Niccolo Bolli iD, Noemi Puig, Cristina João iD

Cancers · 17.04.2026 · 18 (8) · 1275

DOI: 10.3390/cancers18081275 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.04.2026. Verfasst von Joana Caetano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hemato-Oncology Unit, Fundação Champalimaud, 1400-038 Lisbon, Portugal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Portuguese Society of Hematology—Portuguese Group of Multiple Myeloma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma is a complex hematologic malignancy characterized by significant biological heterogeneity, a relapsing–remission clinical course, and a continuously evolving therapeutic landscape. Accurate and timely laboratory assessment is central to disease management, supporting diagnosis, risk stratification, evaluation of treatment response, and long-term monitoring. Despite major advances in therapy, a critical need remains for laboratory tools that can detect disease with greater sensitivity, capture spatial and clonal tumor heterogeneity, and reflect the true depth of treatment response beyond conventional serological and bone marrow-based criteria. Recent laboratory innovations have the potential to transform myeloma care by enabling earlier detection, more accurate prognostication, and personalized therapeutic strategies. This review focuses specifically on innovative laboratory technologies for the diagnosis of multiple myeloma and the evaluation of treatment response. Within this scope, we examine the current diagnostic approaches and the role of high-throughput technologies for measurable residual disease assessment. We explore the emerging role of liquid biopsy approaches, including circulating tumor cells, cell-free DNA/RNA, and mass spectrometry for ultrasensitive detection of monoclonal proteins. We further discuss novel molecular biomarkers and the integration of artificial intelligence and machine learning tools to enhance data interpretation. The innovations reviewed here represent a shift in the contribution of laboratory medicine to myeloma care, offering a more precise, less invasive, and biologically informative framework for targeted and adaptive clinical decisions.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligencecell-free DNAcirculating tumor cellsdiagnosismass spectrometrymeasurable residual diseasemultiple myelomaprognosis

Autor:innen und Institutionen

  • Hemato-Oncology Unit, Fundação Champalimaud, 1400-038 Lisbon, Portugal.
  • NOVA Medical School, NOVA University of Lisbon, 1169-056 Lisbon, Portugal.
  • Clinical Pathology Department, Unidade Local de Saúde Trás-os-Montes e Alto Douro, 5000-508 Vila Real, Portugal.
  • Hemato-Oncology Unit, CUF Hospital Cascais, 2750-663 Cascais, Portugal.
  • Hematology Department, Unidade Local de Saúde São João, 4200-319 Porto, Portugal.
  • Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology (IPATIMUP), Universidade do Porto, 4200-135 Porto, Portugal.

ORCID-Profile: Joana Caetano, Adriana Roque, Niccolo Bolli, Cristina João

Förderung

  • Portuguese Society of Hematology—Portuguese Group of Multiple Myeloma

Zitieren

APA

Caetano, J., Pires, A. M., Costa, C., Bergantim, R., Roque, A., Ferraz, P., Cunha, M. R., Bolli, N., Puig, N., & João, C. (2026). How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care. Cancers, 18(8), 1275. https://doi.org/10.3390/cancers18081275

Vancouver

Caetano J, Pires AM, Costa C, Bergantim R, Roque A, Ferraz P, et al. How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care. Cancers. 2026;18(8):1275. doi:10.3390/cancers18081275

BibTeX
@article{Caetano2026,
  author = {Caetano, Joana and Pires, Ana Marta and Costa, Carlos and Bergantim, Rui and Roque, Adriana and Ferraz, Patrícia and Cunha, Maria Rosário and Bolli, Niccolo and Puig, Noemi and João, Cristina},
  title = {How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1275},
  doi = {10.3390/cancers18081275}
}
Kostenlos starten →